Cars.com
CARS
Lantheus
LNTH
Halozyme Therapeutics
HALO
DOMINOS PIZZA ENTERPRISES LIMITED UNSP ADR EACH REPR 0.5 ORD SHS
DMZPY
Collegium Pharmaceutical
COLL
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 64.03%174.43M | 65.74%46.72M | 77.27%44.97M | 34.48%37.21M | 81.30%45.54M | 8.57%106.34M | 4.32%28.19M | -1.09%25.37M | 47.34%27.67M | -5.23%25.12M |
Operating revenue | 64.03%174.43M | 59.68%46.72M | 74.19%44.03M | 31.76%36.22M | 83.47%44.62M | 8.57%106.34M | 8.28%29.26M | -1.44%25.28M | 52.49%27.49M | -6.99%24.32M |
Cost of revenue | 61.33%90.17M | 67.30%24.81M | 52.73%21.71M | 58.54%22.3M | 66.32%21.35M | -8.22%55.89M | -6.45%14.83M | -13.47%14.21M | -1.99%14.06M | -10.02%12.84M |
Gross profit | 67.02%84.26M | 64.00%21.91M | 108.54%23.26M | 9.60%14.91M | 96.95%24.19M | 36.16%50.45M | 19.61%13.36M | 20.98%11.15M | 207.25%13.6M | 0.36%12.28M |
Operating expense | 92.99%219.02M | 82.72%51.64M | 65.93%47.56M | 97.67%56.9M | 126.96%62.92M | -18.74%113.49M | 2.22%28.26M | -17.70%28.66M | -32.57%28.78M | -30.24%27.72M |
Selling and administrative expenses | 78.90%156.61M | 76.02%37.59M | 54.33%34.4M | 66.70%37.67M | 120.44%46.94M | -14.41%87.54M | 5.59%21.35M | -15.37%22.29M | -24.88%22.6M | -31.03%21.3M |
Research and development costs | 140.52%62.41M | 103.40%14.05M | 106.53%13.16M | 210.83%19.22M | 148.56%15.98M | -30.59%25.95M | -6.95%6.91M | -24.94%6.37M | -50.94%6.18M | -27.48%6.43M |
Operating profit | -113.77%-134.76M | -99.49%-29.74M | -38.78%-24.3M | -176.56%-41.99M | -150.83%-38.74M | 38.57%-63.04M | 9.56%-14.91M | 31.63%-17.51M | 60.32%-15.18M | 43.85%-15.44M |
Net non-operating interest income expense | 469.67%16.88M | 163.64%3.32M | 1,059.12%3.94M | 1,721.31%4.44M | 7,086.11%5.17M | -5.45%-4.57M | -338.91%-5.22M | 132.41%340K | 122.98%244K | 106.99%72K |
Non-operating interest expense | ---- | ---- | ---- | ---- | ---- | 5.45%4.57M | ---- | ---- | ---- | ---- |
Total other finance cost | ---16.88M | ---3.32M | -1,059.12%-3.94M | -1,721.31%-4.44M | -7,086.11%-5.17M | ---- | ---- | ---340K | ---244K | ---72K |
Other net income (expense) | -209.76%-20.44M | -3,968.06%-7.39M | -71.02%-6.46M | -350.81%-8.12M | 226.72%1.53M | 92.33%-6.6M | 106.16%191K | -8.47%-3.78M | 93.03%-1.8M | 97.50%-1.21M |
Special income (charges) | -12.57%-15.27M | 52.45%-3.08M | -102.51%-7.42M | -276.31%-8.53M | 427.48%3.77M | 0.21%-13.56M | -39.96%-6.48M | -7.10%-3.66M | -655.67%-2.27M | ---1.15M |
-Less:Restructuring and merger&acquisition | 12.57%15.27M | -52.45%3.08M | 102.51%7.42M | 276.31%8.53M | -427.48%-3.77M | -0.21%13.56M | 39.96%6.48M | 7.10%3.66M | 655.67%2.27M | --1.15M |
Other non- operating income (expenses) | -174.28%-5.17M | -164.56%-4.31M | 932.17%957K | -11.59%412K | -3,686.44%-2.23M | 156.56%6.96M | 336.87%6.67M | -82.54%-115K | 114.39%466K | 99.44%-59K |
Income before tax | -86.39%-138.31M | -69.53%-33.8M | -28.04%-26.82M | -172.79%-45.66M | -93.18%-32.03M | 61.54%-74.2M | 4.03%-19.94M | 30.50%-20.95M | 74.31%-16.74M | 78.43%-16.58M |
Income tax | 26.77%573K | 267.90%272K | 136.00%118K | -81.73%55K | -51.33%128K | 115.97%452K | -331.43%-162K | 107.01%50K | 118.66%301K | 145.82%263K |
Net income | -86.03%-138.89M | -72.29%-34.07M | -28.29%-26.94M | -168.30%-45.72M | -90.92%-32.16M | 60.73%-74.66M | 5.13%-19.78M | 28.64%-21M | 73.18%-17.04M | 77.92%-16.84M |
Net income continuous Operations | -86.03%-138.89M | -72.29%-34.07M | -28.29%-26.94M | -168.30%-45.72M | -90.92%-32.16M | 60.73%-74.66M | 5.13%-19.78M | 28.64%-21M | 73.18%-17.04M | 77.92%-16.84M |
Minority interest income | ||||||||||
Net income attributable to the parent company | -86.03%-138.89M | -72.29%-34.07M | -28.29%-26.94M | -168.30%-45.72M | -90.92%-32.16M | 60.73%-74.66M | 5.13%-19.78M | 28.64%-21M | 73.18%-17.04M | 77.92%-16.84M |
Preferred stock dividends | 46.01M | 46.01M | ||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | -147.67%-184.9M | -72.29%-34.07M | -28.29%-26.94M | -168.30%-45.72M | -364.12%-78.17M | 60.73%-74.66M | 5.13%-19.78M | 28.64%-21M | 73.18%-17.04M | 77.92%-16.84M |
Basic earnings per share | 44.68%-0.52 | 64.00%-0.09 | 74.07%-0.07 | 45.45%-0.12 | -28.57%-0.27 | 61.32%-0.94 | 3.85%-0.25 | 27.03%-0.27 | 73.17%-0.22 | 78.79%-0.21 |
Diluted earnings per share | 44.68%-0.52 | 64.00%-0.09 | 74.07%-0.07 | 45.45%-0.12 | -28.57%-0.27 | 61.32%-0.94 | 3.85%-0.25 | 27.03%-0.27 | 73.17%-0.22 | 78.79%-0.21 |
Dividend per share | ||||||||||
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |